Prosecution Insights
Prosecution Insights
10 pending office actions • 7 art units • 9 examiners • 0 of 10 (0%) have an AI response strategy ready • 16 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 7 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 7 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (20%) |
| §103 only | 1 (10%) |
| §112 only | 2 (20%) |
| Double-patenting only | 1 (10%) |
| Double-patenting + other | 1 (10%) |
| Multi-statute (no §101) | 3 (30%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DAHLE, CHUN WU | 2 | 49.8% | +51.4% |
| AEDER, SEAN E | 1 | 56.9% | +19.9% |
| OUSPENSKI, ILIA I | 1 | 77.5% | +20.4% |
| MOSELEY II, NELSON B | 1 | 67.8% | +41.6% |
| SHUPE, ELIZABETH A | 1 | 65.7% | +46.8% |
| HAM, JIEUN | 1 | 50.0% | +62.5% |
| YOUTCHOM PENDIE, EMMANUEL LED | 1 | 55.6% | +50.0% |
| CARTER, SANDRA DILLAHUNT | 1 | 56.1% | +29.7% |
| PATTERSON, SARAH COOPER | 1 | 58.3% | +56.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17692755 | IL15/IL15Ralpha HETERODIMERIC Fc-FUSION PROTEINS | PATTERSON, SARAH COOPER | 46d overdue |
| 18300302 | ANTIBODIES THAT BIND PD-L1, PD-L2, AND/OR CD28 | HAM, JIEUN | 1d overdue |
| 18456317 | OPTIMIZED Fc VARIANTS | DAHLE, CHUN WU | 16d |
| 18248030 | BIOMARKERS, METHODS, AND COMPOSITIONS FOR TREATING AUTOIMMUNE DISEASE INCLUDING SYSTEMIC LUPUS ERYTHEMATOUS (SLE) | DAHLE, CHUN WU | — |
| 17815194 | IL-18-FC FUSION PROTEINS | CARTER, SANDRA DILLAHUNT | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18033165 | ANTI-CD20 ANTIBODIES AND THERAPEUTIC USES THEREOF | SHUPE, ELIZABETH A | 97d overdue |
| 17692755 | IL15/IL15Ralpha HETERODIMERIC Fc-FUSION PROTEINS | PATTERSON, SARAH COOPER | 46d overdue |
| 18300302 | ANTIBODIES THAT BIND PD-L1, PD-L2, AND/OR CD28 | HAM, JIEUN | 1d overdue |
| 18587839 | HETERODIMERIC ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENS | AEDER, SEAN E | 16d |
| 18456317 | OPTIMIZED Fc VARIANTS | DAHLE, CHUN WU | 16d |
| 18053325 | BISPECIFIC ANTIBODIES THAT BIND TO B7H3 AND NKG2D | YOUTCHOM PENDIE, EMMANUEL LED | 29d |
| 18452395 | BISPECIFIC IMMUNOMODULATORY ANTIBODIES THAT BIND COSTIMULATORY AND CHECKPOINT RECEPTORS | OUSPENSKI, ILIA I | 46d |
| 18348244 | HETERODIMERIC ANTIBODIES THAT BIND CD3 AND CLDN6 | MOSELEY II, NELSON B | — |
| Art Unit | Apps |
|---|---|
| 1642 | 2 |
| 1641 | 2 |
| 1643 | 2 |
| 1644 | 1 |
| 1647 | 1 |
| 1674 | 1 |
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18587839 | HETERODIMERIC ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENS | AEDER, SEAN E | 1642 | §112Other | Non-Final OA | 16d | Pending | Feb 26, 2024 |
| 18456317 | OPTIMIZED Fc VARIANTS | DAHLE, CHUN WU | 1641 | §101§112Other | Non-Final OA | 16d | Pending | Aug 25, 2023 |
| 18452395 | BISPECIFIC IMMUNOMODULATORY ANTIBODIES THAT BIND COSTIMULATORY AND CHECKPOINT RECEPTORS | OUSPENSKI, ILIA I | 1644 | §112Other | Non-Final OA | 46d | Pending | Aug 18, 2023 |
| 18348244 | HETERODIMERIC ANTIBODIES THAT BIND CD3 AND CLDN6 | MOSELEY II, NELSON B | 1642 | §112DPOther | Non-Final OA | — | Pending | Jul 06, 2023 |
| 18033165 | ANTI-CD20 ANTIBODIES AND THERAPEUTIC USES THEREOF | SHUPE, ELIZABETH A | 1643 | DP | Final Rejection | 97d overdue | Pending | Apr 21, 2023 |
| 18300302 | ANTIBODIES THAT BIND PD-L1, PD-L2, AND/OR CD28 | HAM, JIEUN | 1643 | §102§112Other | Non-Final OA | 1d overdue | Pending | Apr 13, 2023 |
| 18248030 | BIOMARKERS, METHODS, AND COMPOSITIONS FOR TREATING AUTOIMMUNE DISEASE INCLUDING SYSTEMIC LUPUS ERYTHEMATOUS (SLE) | DAHLE, CHUN WU | 1641 | §101§112 | Non-Final OA | — | Pending | Apr 05, 2023 |
| 18053325 | BISPECIFIC ANTIBODIES THAT BIND TO B7H3 AND NKG2D | YOUTCHOM PENDIE, EMMANUEL LED | 1647 | §103 | Non-Final OA | 29d | Pending | Nov 07, 2022 |
| 17815194 | IL-18-FC FUSION PROTEINS | CARTER, SANDRA DILLAHUNT | 1674 | §102§103§112 | Non-Final OA | — | Pending | Jul 26, 2022 |
| 17692755 | IL15/IL15Ralpha HETERODIMERIC Fc-FUSION PROTEINS | PATTERSON, SARAH COOPER | 1675 | §103§112Other | Non-Final OA | 46d overdue | Pending | Mar 11, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial